Debiopharm announces FDA fast track designation for lunresertib in combination with zedoresertib for genomic defined platinum-resistant ovarian cancer

23 April 2026 - Debiopharm today announced that the US FDA has granted fast track designation to the combination of its ...

Read more →

Labcorp launches FDA approved companion diagnostic to identify patients with ovarian cancer eligible for Keytruda

22 April 2026 - Labcorp today announced the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only companion ...

Read more →

Ojemda approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration

22 April 2026 - Approval is based on pivotal Phase 2 FIREFLY-1 data demonstrating meaningful and durable tumour responses. ...

Read more →

New life-extending treatment given the green light for people with rare form of bile duct cancer

21 April 2026 - A new targeted treatment for a rare and aggressive form of bile duct cancer has been recommended ...

Read more →

BBOT granted US FDA fast track designation for BBO-11818 for the treatment of adult patients with advanced KRAS mutant pancreatic ductal adenocarcinoma

20 April 2026 - BridgeBio Oncology Therapeutics today announced that the US FDA has granted fast track designation to BBO-11818 for ...

Read more →

US FDA grants priority review to sBLA for Padcev and Keytruda as peri-operative treatment for muscle invasive bladder cancer regardless of cisplatin eligibility

20 April 2026 - Astellas Pharma and Pfizer announced that the US FDA accepted for triority review a supplemental biologics license ...

Read more →

New take at home drug recommended for people with chronic lymphocytic leukaemia

17 April 2026 - NICE has recommended a new take at home tablet for some people with chronic lymphocytic leukaemia whose ...

Read more →

The Australian Government is continuing to deliver cheaper medicines with Australians living with lung or bladder cancer to pay less for new and expanded PBS medicines

16 April 2026 - The Australian Government is continuing to deliver cheaper medicines with Australians living with lung or bladder ...

Read more →

Opna Bio announces fast track designation granted to OPN-6602 for the treatment of multiple myeloma

15 April 2026 - Opna Bio today announced that the US FDA has granted fast track designation to OPN-6602, a dual ...

Read more →

Partner Therapeutics announces submission of supplemental biologics license application to FDA for Bizengri (zenocutuzumab-zbco) in NRG1 fusion positive cholangiocarcinoma

14 April 2026 - Partner Therapeutics announces the submission of a supplemental biologics license application to the US FDA for Bizengri ...

Read more →

Renaissance Pharma secures FDA fast track designation for daretabart (hu1418K322A) in high risk neuroblastoma

14 April 2026 - Renaissance Pharma Limited, an Essential Pharma company, today announces that the US FDA has granted fast track ...

Read more →

Cancer patient’s plea for Pfizer to rejoin PBS talks on breakthrough drug

14 April 2026 - Pharmaceutical giant Pfizer has abandoned negotiations to have a breakthrough cancer drug listed on the Pharmaceutical ...

Read more →

Celltrion’s ADC candidate CT-P71 wins FDA fast track in urothelial cancer

9 April 2026 - Celltrion announced Thursday that the US FDA has granted fast track designation to its antibody-drug conjugate ...

Read more →

PHARMAC to fund two new combination treatments, and widen access to another, for people with a type of blood cancer

9 April 2026 - From 1 May 2026, people living with chronic lymphocytic leukaemia will be able to access two ...

Read more →

Cancer clinicians call for three actions Canada's health systems should take to improve cancer care

7 April 2026 - April Cancer Awareness Month a good time for concrete action ...

Read more →